Romano’s appointment as the India-based surgical robot maker’s CFO goes into effect on Aug. 3. She will be based in the U.S., where SS Innovations operates out of Fort Lauderdale, Florida.
She joins SS Innovations as the company looks to advance its surgical robotic capabilities, having submitted its Mantra 3 system to the FDA in December 2025. Its submission seeks indications in general, urological, colorectal, gynecological and cardiac surgery. In the meantime, the company also continues to demonstrate its telerobotic capabilities through long-distance remote surgery.
Mantra features a modular, 3D vision, open-console design with ergonomics that the company describes as superior. It engages machine learning models to improve safety and efficiency during procedures.
Romano comes to SS Innovations from another surgical robot maker, Vicarious Surgical, where she was named CFO in March 2025. There, she led financial and operational initiatives to reduce cash burn, strengthen the balance sheet and support strategic objectives.
Prior to Vicarious Surgical, Romano served as CFO of Entero Therapeutics and Kiora Pharmaceuticals. Her track record includes the raising of more than $100 million throughout her career. She began her career as an auditor at PricewaterhouseCoopers.
Commentary from SS Innovations leadership
Dr. Sudhir Srivastava, chair and CEO of SS Innovations, said:
“We are thrilled to welcome Sarah as our chief financial officer at this critical moment in our growth journey. As we continue our global expansion, including pursuing U.S. FDA approval of our advanced, cost-effective SSi Mantra surgical robotic system, Sarah brings strong financial leadership, keen strategic vision, and extensive capital markets experience. She will play an integral role in scaling and enhancing our financial operations to accommodate our anticipated growth.”
Romano added:
“I am delighted for this opportunity to collaborate closely with Dr. Sudhir and the leadership team as SS Innovations delivers on its mission to democratize global access to cutting-edge surgical robotic care.”
